Janney Montgomery Scott LLC increased its position in Humana Inc (NYSE:HUM) by 92.8% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 5,535 shares of the insurance provider’s stock after purchasing an additional 2,664 shares during the quarter. Janney Montgomery Scott LLC’s holdings in Humana were worth $1,415,000 as of its most recent SEC filing.
Several other hedge funds have also recently modified their holdings of the company. Cornerstone Advisors Inc. raised its holdings in Humana by 9.9% in the 3rd quarter. Cornerstone Advisors Inc. now owns 388 shares of the insurance provider’s stock valued at $99,000 after acquiring an additional 35 shares during the period. Regentatlantic Capital LLC raised its holdings in Humana by 0.4% in the 2nd quarter. Regentatlantic Capital LLC now owns 9,617 shares of the insurance provider’s stock valued at $2,551,000 after acquiring an additional 42 shares during the period. Ballentine Partners LLC raised its holdings in Humana by 2.5% in the 3rd quarter. Ballentine Partners LLC now owns 1,751 shares of the insurance provider’s stock valued at $448,000 after acquiring an additional 42 shares during the period. Cim Investment Mangement Inc. raised its holdings in Humana by 4.3% in the 2nd quarter. Cim Investment Mangement Inc. now owns 1,125 shares of the insurance provider’s stock valued at $298,000 after acquiring an additional 46 shares during the period. Finally, Savant Capital LLC raised its holdings in Humana by 2.5% in the 2nd quarter. Savant Capital LLC now owns 1,968 shares of the insurance provider’s stock valued at $522,000 after acquiring an additional 48 shares during the period. 92.93% of the stock is currently owned by institutional investors.
Shares of NYSE:HUM opened at $315.14 on Friday. The company has a quick ratio of 1.75, a current ratio of 1.75 and a debt-to-equity ratio of 0.37. The firm has a market cap of $39.82 billion, a PE ratio of 21.66, a PEG ratio of 1.27 and a beta of 0.85. The company’s 50 day moving average price is $276.72 and its two-hundred day moving average price is $270.55. Humana Inc has a 12-month low of $225.65 and a 12-month high of $353.05.
Humana (NYSE:HUM) last posted its quarterly earnings results on Wednesday, November 6th. The insurance provider reported $5.03 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $4.58 by $0.45. The business had revenue of $16.24 billion for the quarter, compared to analyst estimates of $16.15 billion. Humana had a net margin of 4.13% and a return on equity of 22.47%. The firm’s revenue for the quarter was up 14.3% on a year-over-year basis. During the same quarter last year, the business posted $4.58 EPS. On average, research analysts expect that Humana Inc will post 17.75 EPS for the current year.
The company also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Tuesday, December 31st will be given a dividend of $0.55 per share. The ex-dividend date of this dividend is Monday, December 30th. This represents a $2.20 annualized dividend and a dividend yield of 0.70%. Humana’s dividend payout ratio is 15.12%.
Several research analysts have weighed in on the stock. Deutsche Bank started coverage on shares of Humana in a report on Thursday, September 12th. They issued a “hold” rating and a $300.00 price target on the stock. Morgan Stanley decreased their target price on shares of Humana from $342.00 to $337.00 and set an “overweight” rating on the stock in a research report on Thursday, September 26th. JPMorgan Chase & Co. increased their target price on shares of Humana from $288.00 to $322.00 and gave the stock an “overweight” rating in a research report on Thursday, August 1st. BMO Capital Markets lowered shares of Humana from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $345.00 to $290.00 in a research report on Monday, September 30th. Finally, Berenberg Bank restated a “buy” rating on shares of Humana in a research report on Monday, October 21st. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and seventeen have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $333.05.
In related news, insider Brian P. Leclaire sold 7,239 shares of the stock in a transaction that occurred on Thursday, August 22nd. The shares were sold at an average price of $289.70, for a total transaction of $2,097,138.30. Following the sale, the insider now owns 12,994 shares in the company, valued at approximately $3,764,361.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.54% of the company’s stock.
Humana Company Profile
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Further Reading: Bid-Ask Spread
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.